Home > Publications Database > Exploring the origins of frequent tau-PET signal in vermal and adjacent regions. > print

001     280249
005     20250907001838.0
024 7 _ |a 10.1007/s00259-025-07199-x
|2 doi
024 7 _ |a pmid:40100387
|2 pmid
024 7 _ |a pmc:PMC12316827
|2 pmc
024 7 _ |a 1619-7070
|2 ISSN
024 7 _ |a 1619-7089
|2 ISSN
024 7 _ |a altmetric:175271097
|2 altmetric
037 _ _ |a DZNE-2025-00927
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kling, Agnes
|b 0
245 _ _ |a Exploring the origins of frequent tau-PET signal in vermal and adjacent regions.
260 _ _ |a Heidelberg [u.a.]
|c 2025
|b Springer-Verl.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1756886671_1279
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Off-target binding remains a significant challenge in tau-PET neuroimaging. While off-targets including monoamine oxidase enzymes and neuromelanin-containing cells have been identified, recent studies indicated a relevant binding of novel tau tracers to melanin-containing structures. To date, little is known about the effect of melanocytes in the meninges on tracer signals in brain PET data. Thus, we aimed to identify the target structure causal for the frequently observed [18F]PI-2620 PET signal in the vermis and adjacent cerebellar regions.274 participants underwent dynamic [18F]PI-2620 tau-PET: 3/4R-tauopathies (n = 85), 4R-tauopathies (n = 147), tau-negative disease controls (n = 24), and healthy controls (n = 18). Standardized uptake value ratio (SUVR) and kinetic parameters including the distribution volume ratio (DVR), tracer clearance (k2) and relative perfusion (R1), were compared among the cohorts and sexes using the Automated Anatomical Labelling (AAL) atlas. Age and p-Tau levels in cerebrospinal fluid (CSF) were assessed for their relationship with vermal tau-PET signal. Furthermore, we combined autoradiographic and histochemical experiments on post-mortem brain tissue of deceased patients (n = 9).Male participants revealed higher mean vermal [18F]PI-2620 DVR (0.95 ± 0.13; vs. females 0.88 ± 0.10, p < 0.0001). Sex-related differences were most pronounced in the 3/4R-tauopathy cohort (p < 0.0001). Mean SUVRVer/Cbl, k2 and correlation analyses of kinetic parameters did not differ among groups. Histological assessments revealed co-localization of leptomeningeal pigmented cells with strong autoradiography signal spots within the vermal fissures. Tau-related autoradiography signals, age or p-Tau levels did not correlate significantly with tau-PET signals. Iron deposits did not cause relevant autoradiography signals in the vermis.Leptomeningeal melanocytes are the primary target structure for [18F]PI-2620 PET binding in anterior vermis, whereas iron and tau deposits do not contribute significantly.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Cerebellum
|2 Other
650 _ 7 |a Melanocytes
|2 Other
650 _ 7 |a Meninges
|2 Other
650 _ 7 |a Off-target binding
|2 Other
650 _ 7 |a Tau-PET
|2 Other
650 _ 7 |a Vermis
|2 Other
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a ((18)F)PI-2620
|2 NLM Chemicals
650 _ 7 |a Fluorine Radioisotopes
|2 NLM Chemicals
650 _ 7 |a Pyridines
|2 NLM Chemicals
650 _ 2 |a Neuroimaging: methods
|2 MeSH
650 _ 2 |a tau Proteins: analysis
|2 MeSH
650 _ 2 |a tau Proteins: metabolism
|2 MeSH
650 _ 2 |a Positron-Emission Tomography: methods
|2 MeSH
650 _ 2 |a Fluorine Radioisotopes: administration & dosage
|2 MeSH
650 _ 2 |a Fluorine Radioisotopes: pharmacology
|2 MeSH
650 _ 2 |a Cerebellar Vermis: diagnostic imaging
|2 MeSH
650 _ 2 |a Cerebellar Vermis: metabolism
|2 MeSH
650 _ 2 |a Cerebellar Vermis: pathology
|2 MeSH
650 _ 2 |a Tauopathies: diagnostic imaging
|2 MeSH
650 _ 2 |a Tauopathies: metabolism
|2 MeSH
650 _ 2 |a Tauopathies: pathology
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Case-Control Studies
|2 MeSH
650 _ 2 |a Pyridines
|2 MeSH
700 1 _ |a Kusche-Palenga, Julia
|b 1
700 1 _ |a Palleis, Carla
|0 P:(DE-2719)9000852
|b 2
|u dzne
700 1 _ |a Jäck, Alexander
|0 P:(DE-2719)9002626
|b 3
|u dzne
700 1 _ |a Bernhardt, Alexander M
|0 P:(DE-2719)9002620
|b 4
|u dzne
700 1 _ |a Frontzkowski, Lukas
|b 5
700 1 _ |a Römer, Sebastian
|0 P:(DE-2719)9003667
|b 6
|u dzne
700 1 _ |a Slemann, Luna
|b 7
700 1 _ |a Zaganjori, Mirlind
|b 8
700 1 _ |a Scheifele, Maximilian
|b 9
700 1 _ |a Paeger, Lars
|0 P:(DE-2719)9002242
|b 10
|u dzne
700 1 _ |a Bischof, Gérard N
|0 P:(DE-2719)9002485
|b 11
700 1 _ |a van Eimeren, Thilo
|0 P:(DE-2719)2812285
|b 12
|u dzne
700 1 _ |a Drzezga, Alexander
|0 P:(DE-2719)2811239
|b 13
|u dzne
700 1 _ |a Sabri, Osama
|0 P:(DE-2719)2814810
|b 14
|u dzne
700 1 _ |a Rullmann, Michael
|b 15
700 1 _ |a Barthel, Henryk
|b 16
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 17
|u dzne
700 1 _ |a Herms, Jochen
|0 P:(DE-2719)2810441
|b 18
|u dzne
700 1 _ |a Franzmeier, Nicolai
|b 19
700 1 _ |a Höglinger, Günter
|0 P:(DE-2719)2811373
|b 20
|u dzne
700 1 _ |a Roeber, Sigrun
|b 21
700 1 _ |a Brendel, Matthias
|0 P:(DE-2719)9001539
|b 22
|u dzne
700 1 _ |a Gnoerich, Johannes
|0 P:(DE-2719)9001652
|b 23
|e Last author
|u dzne
773 _ _ |a 10.1007/s00259-025-07199-x
|g Vol. 52, no. 10, p. 3519 - 3533
|0 PERI:(DE-600)2098375-X
|n 10
|p 3519 - 3533
|t European journal of nuclear medicine and molecular imaging
|v 52
|y 2025
|x 1619-7070
856 4 _ |u https://pub.dzne.de/record/280249/files/DZNE-2025-00927%20SUP1.docx
856 4 _ |u https://pub.dzne.de/record/280249/files/DZNE-2025-00927%20SUP2.docx
856 4 _ |y Restricted
|u https://pub.dzne.de/record/280249/files/DZNE-2025-00927.pdf
856 4 _ |u https://pub.dzne.de/record/280249/files/DZNE-2025-00927.pdf?subformat=pdfa
|x pdfa
|y Restricted
909 C O |o oai:pub.dzne.de:280249
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9000852
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9002626
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9002620
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 6
|6 P:(DE-2719)9003667
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)9002242
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2812285
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2811239
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 14
|6 P:(DE-2719)2814810
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2811659
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 18
|6 P:(DE-2719)2810441
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 20
|6 P:(DE-2719)2811373
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 22
|6 P:(DE-2719)9001539
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 23
|6 P:(DE-2719)9001652
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-05
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-05
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-05
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J NUCL MED MOL I : 2022
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-05
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-05
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-05
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-05
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR J NUCL MED MOL I : 2022
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-05
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 1
920 1 _ |0 I:(DE-2719)1110001
|k AG Herms
|l Translational Brain Research
|x 2
920 1 _ |0 I:(DE-2719)1011202
|k AG Boecker
|l Positron Emissions Tomography (PET)
|x 3
920 1 _ |0 I:(DE-2719)1111016
|k AG Levin
|l Clinical Neurodegeneration
|x 4
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1110007
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1110001
980 _ _ |a I:(DE-2719)1011202
980 _ _ |a I:(DE-2719)1111016
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21